Melatonin and Aromatase in Breast Cancer

Abstract

It has been shown that melatonin, the pineal gland hormone, is an oncostatic agent that arrests the growth of different kinds of tumors, especially mammary tumors whose growth is dependent of estrogens.

In vivo and in vitro previous reports point to the hypothesis that melatonin interplays with estrogen-signaling pathways at three different levels: (a) an indirect mechanism, by interfering with the hypothalamic-pituitary-reproductive axis, in such way that the level of plasma estrogens synthesized by the gonadal glands are down-regulated, (b) direct mechanism of the melatonin at cell cancer level, disrupting the activation of estradiol receptors, therefore behaving as a selective estrogen receptor modulator (SERM), and finally (c) by regulating the enzymes involved in the biosynthesis of estrogens in other tissues, thus behaving as a selective estrogen enzyme modulator (SEEM).

Melatonin has been proved to alter both the activity and expression of several enzymes implicated in steroidal hormones synthesis, such as aromatase, the complex necessary to convert androgens into estrogens, in different kind of cells, such as malignant epithelial cells from breast cancer and cells surrounding the tumor: fibroblasts and endothelial cells, therefore protecting the mammary gland from estrogen induced proliferation and transformation.

The aim of the present review is to summarize the recent findings describing how melatonin is able to modulate aromatase.

Antiaromatase drugs are currently employed in breast cancer therapy and therefore melatonin modulation of aromatase points to this indolamine as a potential anticancer drug in estrogen-dependent mammary cancer prevention and treatment.

 

 

About this publication.

 

See also:

- About Melatonin;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonisn, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma;

- Recurrent Glioblastoma Multiforme (grade IV – WHO 2007): a case of complete objective response achieved by means of the concomitant administration of Somatostatin and Octreotide – Retinoids – Vitamin E – Vitamin D3 – Vitamin C – Melatonin – D2 R agonists (Di Bella Method – DBM) associated with Temozolomide;

- Chronic Lymphocytic Leukemia: Long-Lasting Remission with Combination of Cyclophosphamide, Somatostatin, Bromocriptine, Retinoids, Melatonin, and ACTH;

- Pancreatic Adenocarcinoma: clinical records on 17 patients treated with Di Bella's Method;

- The Di Bella Method Increases by the 30% the survival rate for Pancreas tumors and for this reason should be proposed as first line therapy for this type of cancer.